Pressure BioSciences (OTCQB: PBIO) (“PBI”), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumable products and specialty services to the life sciences field, and Artisan Industries, a worldwide leader in providing purification and separation technologies for the process industries, announced a strategic agreement between the companies. Under the agreement, PBIO will rent space and ancillary support in Artisan’s state-of-the-art facilities, dramatically increasing PBIO’s manufacturing capacity for servicing the needs of its growing portfolio of UltraShear Technology(TM) (“UltraShear(TM)” or “UST(TM)”)-based nanoemulsion clients. In addition, the relationship is expected to facilitate discussions between the companies towards an agreement that would secure Artisan as the exclusive manufacturer of PBIO’s revolutionary UltraShear equipment (the “BaroShear(TM)” line of products). “We are excited to have reached an agreement on a leap forward in our manufacturing capacity, capabilities and strategy that allows us to quickly transition from small, pilot scale lots for test markets (limitation of our current facilities) into large-scale servicing of UltraShear toll manufacturing contracts,” said Richard T. Schumacher, president and CEO of PBIO. “We expect that this transition will be completed over the next 30 days. We will also be actively exploring the potential for this relationship to produce an equipment manufacturing partnership, one that can accelerate our execution in scaling large UltraShear partners into our lease-and-license business model for their in-house manufacturing capacity, beginning in 2024.”
To view the full press release, visit https://ibn.fm/MTAy9
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Its products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Pressure BioSciences’ primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) patented technology from BaroFold Inc. (the BaroFold technology) that allows entry into the bio-pharma contract services sector, and (2) recently-patented, scalable, high-efficiency, pressure-based UltraShear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information about the company, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
